Cytogen Cancer Treatment Effective In Study
July 6, 1999
Dow Jones Newswires
PRINCETON, N.J. -- Cytogen Corp. (CYTO) said a study published in Cancer Research supports its prostate specific membrane antigen, or PSMA, as a diagnostic and therapeutic agent for a wide variety of cancers.
In a press release Monday, Cytogen said PSMA had enzymatic activity and may regulate one or more metabolic pathways.
PSMA is a protein abundantly expressed on the surface of cancer cells.
Cytogen holds exclusive worldwide rights to PSMA under a license from Memorial Sloan-Kettering Cancer Center.
As reported June 16, Cytogen and Progenics Pharmaceuticals Inc. (PGNX) formed a venture to develop vaccine and antibody-based therapeutic products.
Cytogen said the products will use its PSMA technology.
Under the terms of the venture agreement, Progenics will conduct preclinical and clinical development of therapeutic antibodies and vaccines that treat prostate and potentially other cancer types. Cytogen will assume exclusive North American marketing rights for products resulting from the venture and have an option to market outside the U.S.
Cytogen develops treatments for cancer and urological diseases.
Progenics , Tarrytown, N.Y., develops and markets products to treat cancer and viral diseases.
Jim
|
